Safety and efficacy of StarClose SE Vascular Closure System in high-risk liver interventional oncology patients

Ron C. Gaba, Ahmad Parvinian, Estrellita M. Trinos, Suzanne V. Padayao, Rechel M. Francisco, Felix Y. Yap, M. Grace Knuttinen, Charles A. Owens, James T. Bui

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

PURPOSE: To assess the safety and efficacy of the StarClose SE Vascular Closure System (Abbott Vascular, Abbott Park IL, USA) in high-risk thrombocytopenic and coagulopathic interventional oncology (IO) patients.

METHODS: In this single institution retrospective study, 63 high-risk thrombocytopenic or coagulopathic IO patients (M:F=51:12, mean age 58 years, range 31-88 years) who underwent 83 common femoral arteriotomy closures using the StarClose device were identified among all IO patients (n=131) undergoing StarClose closure (n=177) between 2008-2011. High-risk thrombocytopenia and coagulopathy were defined as platelet count ≤100 10(3)/mL and international normalized ratio (INR) ≥1.5. Procedures included chemoembolization (n=67), radioembolization (n=8), and hepatic arterial mapping with technetium-99m macroaggrated albumin administration (n=8) for treatment of hepatocellular carcinoma (n=79) or liver metastases (n=4). Measured outcomes included technical success of arterial closure and closure-related adverse events, graded according to the Society of Interventional Radiology classification.

RESULTS: In all cases, 5 French common femoral arterial access was used. Platelet count was ≤100 10(3)/mL in 80/83 (96.4%) cases and INR was ≥1.5 in 35/83 (42.2%) cases. Mean pre-procedure platelet count was 71 (range 26-347) 10(3)/mL and mean INR was 1.4 (range 1.0-2.1). The StarClose device effectively sealed the arteriotomy in 83/83 (100%) cases, 60/83 (72.3%) cases were first-time closures, and 20/83 (24.1%) cases were repeat closures. Small groin hematomas, graded as class A minor complications, developed in 3/83 (3.6%) cases. No other complications were encountered.

CONCLUSIONS: The StarClose SE Vascular Closure System confers high technical success and safety in common femoral arteriotomy closure in high-risk IO patients.

Original languageEnglish (US)
Pages (from-to)415-420
Number of pages6
JournalThe journal of vascular access
Volume13
Issue number4
DOIs
StatePublished - Oct 1 2012

ASJC Scopus subject areas

  • Surgery
  • Nephrology

Fingerprint Dive into the research topics of 'Safety and efficacy of StarClose SE Vascular Closure System in high-risk liver interventional oncology patients'. Together they form a unique fingerprint.

  • Cite this

    Gaba, R. C., Parvinian, A., Trinos, E. M., Padayao, S. V., Francisco, R. M., Yap, F. Y., Knuttinen, M. G., Owens, C. A., & Bui, J. T. (2012). Safety and efficacy of StarClose SE Vascular Closure System in high-risk liver interventional oncology patients. The journal of vascular access, 13(4), 415-420. https://doi.org/10.5301/jva.5000068